C-reactive protein relaxes human vessels in vitro

被引:36
作者
Sternik, L
Samee, S
Schaff, HV
Zehr, KJ
Lerman, LO
Holmes, DR
Herrmann, J
Lerman, A
机构
[1] Mayo Clin & Mayo Fdn, Div Cardiovasc Surg, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Div Hypertens, Rochester, MN 55905 USA
关键词
atherosclerosis; C-reactive protein; potassium channels; vasorelaxation; inflammation;
D O I
10.1161/01.ATV.0000033821.96354.90
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-C-reactive protein (CRP) is a sensitive marker of inflammation and a prognostic marker in cardiovascular disease. Evidence suggests direct biological activities of CRP within the vascular wall. The study was designed to examine the vasoreactive effects of CRP. Methods and Results-Human internal mammary artery rings were obtained during cardiovascular bypass surgery and suspended in an organ bath chamber. The rings were precontracted with endothelin-1, and response to cumulative concentrations of CRP was obtained. Experiments were repeated after initial incubation with 20, 40, and 60 mmol/L KCl, the potassium channel blockers BaCL tetraethylammonium chloride, and glibenclamide, and the NO synthase inhibitor N-monomethyl-(L)-arginine and also after removal of the endothelium. CRP caused dose-dependent relaxation of human internal mammary artery rings. which was not affected by preincubation with N-monomethyl-L-arginine or removal of the endothelium. Maximum relaxation response to CRP (79.5+/-10%) was attenuated by KCl (2.5+/-11.5%, P<0.001), BaCl (24.5+/-7.5%, P<0.001), and tetraethylammonium chloride (34.9+/-8.25%. P<0.01) but not by glibenclamide. Conclusions-The present study demonstrates that CRP exerts an endothelium-independent vasorelaxing effect via potassium channels. Thus, the study suggests a role of CRP in the regulation of vascular tone.
引用
收藏
页码:1865 / 1868
页数:4
相关论文
共 25 条
[1]   Complement and atherogenesis - Binding of CRP to degraded, nonoxidized LDL enhances complement activation [J].
Bhakdi, S ;
Torzewski, M ;
Klouche, M ;
Hemmes, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (10) :2348-2354
[2]   Novel clinical markers of vascular wall inflammation [J].
Blake, GJ ;
Ridker, PM .
CIRCULATION RESEARCH, 2001, 89 (09) :763-771
[3]   REGULATION OF ARTERIAL TONE BY ACTIVATION OF CALCIUM-DEPENDENT POTASSIUM CHANNELS [J].
BRAYDEN, JE ;
NELSON, MT .
SCIENCE, 1992, 256 (5056) :532-535
[4]   Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease [J].
Cleland, SJ ;
Sattar, N ;
Petrie, JR ;
Forouhi, NG ;
Elliott, HL ;
Connell, JMC .
CLINICAL SCIENCE, 2000, 98 (05) :531-535
[5]   Function of C-reactive protein [J].
Du Clos, TW .
ANNALS OF MEDICINE, 2000, 32 (04) :274-278
[6]   Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease [J].
Fichtlscherer, S ;
Rosenberger, G ;
Walter, DH ;
Breuer, S ;
Dimmeler, S ;
Zeiher, AM .
CIRCULATION, 2000, 102 (09) :1000-1006
[7]   Insulin and insulin-like growth factor-I cause coronary vasorelaxation in vitro [J].
Hasdai, D ;
Rizza, RA ;
Holmes, DR ;
Richardson, DM ;
Cohen, P ;
Lerman, A .
HYPERTENSION, 1998, 32 (02) :228-234
[8]   Acute systemic inflammation impairs endothelium-dependent dilatation in humans [J].
Hingorani, AD ;
Cross, J ;
Kharbanda, RK ;
Mullen, MJ ;
Bhagat, K ;
Taylor, M ;
Donald, AE ;
Palacios, M ;
Griffin, GE ;
Deanfield, JE ;
MacAllister, RJ ;
Vallance, P .
CIRCULATION, 2000, 102 (09) :994-999
[9]   Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro [J].
Izhar, U ;
Hasdai, D ;
Richardson, DM ;
Cohen, P ;
Lerman, A .
CORONARY ARTERY DISEASE, 2000, 11 (01) :69-76
[10]   C-reactive protein as a cardiovascular risk factor - More than an epiphenomenon? [J].
Lagrand, WK ;
Visser, CA ;
Hermens, WT ;
Niessen, HWM ;
Verheugt, FWA ;
Wolbink, GJ ;
Hack, CE .
CIRCULATION, 1999, 100 (01) :96-102